Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications.

[1]  M. Kollef.  An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Karlowsky,et al.  Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001 , 2003, Antimicrobial Agents and Chemotherapy.

[3]  J. Turnidge,et al.  Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration , 2003, Antimicrobial Agents and Chemotherapy.

[4]  J. Garnacho-Montero,et al.  Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Turnidge,et al.  Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid Chromatography , 2003, Antimicrobial Agents and Chemotherapy.

[6]  L. B. Hovde,et al.  Synergistic Activity of Colistin and Ceftazidime against Multiantibiotic-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model , 2003, Antimicrobial Agents and Chemotherapy.

[7]  T. Nakamura,et al.  Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. , 2003, The Journal of hospital infection.

[8]  E. Giamarellos‐Bourboulis,et al.  Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. , 2002, Diagnostic microbiology and infectious disease.

[9]  D. Raoult,et al.  Colistin: an antimicrobial for the 21st century? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Hodson,et al.  A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis , 2002, European Respiratory Journal.

[11]  C. Cabellos,et al.  Efficacy of Colistin versus β-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii , 2002, Antimicrobial Agents and Chemotherapy.

[12]  H. Elphick,et al.  Colistin stimulates the activity of neutrophil elastase and Pseudomonas aeruginosa elastase , 2002, European Respiratory Journal.

[13]  D. Livermore,et al.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Pachón,et al.  Cerebrospinal Fluid Penetration and Pharmacokinetic/Pharmacodynamic Parameters of Intravenously Administered Colistin in a Case of Multidrug-Resistant Acinetobacter baumannii Meningitis , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  E. Giamarellos‐Bourboulis,et al.  Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. , 2001, Diagnostic microbiology and infectious disease.

[16]  R. Stern,et al.  The Pharmacokinetics of Colistin in Patients with Cystic Fibrosis , 2001, Journal of clinical pharmacology.

[17]  J. Turnidge,et al.  In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis , 2001, Antimicrobial Agents and Chemotherapy.

[18]  Ronald N. Jones,et al.  Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines , 2001, Journal of Clinical Microbiology.

[19]  A. Coates,et al.  Nebulizer choice for inhaled colistin treatment in cystic fibrosis. , 2001, Chest.

[20]  D. Feola,et al.  Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria , 1999, The Annals of pharmacotherapy.

[21]  S. Segal-Maurer,et al.  Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Levin,et al.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Tani,et al.  Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[24]  R. Wise,et al.  A reassessment of the in-vitro activity of colistin sulphomethate sodium. , 1997, The Journal of antimicrobial chemotherapy.

[25]  G. Harrison,et al.  Toxicity of Colistin in Cystic Fibrosis Patients , 1991, DICP : the annals of pharmacotherapy.

[26]  Francis O'Grady,et al.  ANTIBIOTIC AND CHEMOTHERAPY , 1974, The Ulster Medical Journal.